busulfan has been researched along with Minimal Disease, Residual in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " For graft-versus-host disease prophylaxis patients received cyclosporin A (CSA) and methotrexate (MTX) (n=32), MTX alone (n=12), CSA and methylprednisone (n=5), or CSA alone (n=13)." | 3.69 | Long-term leukemia-free survival after allogeneic marrow transplantation in patients with acute myelogenous leukemia. ( Brugger, SA; Dieckmann, KU; Fischer, G; Geissler, K; Greinix, HT; Haas, O; Hinterberger, W; Hocker, P; Jager, U; Kalhs, P; Keil, F; Lechner, K; Linkesch, W; Mannhalter, C; Reiter, E; Schneider, B; Schwarzinger, I, 1996) |
| "Forty-three patients with high-risk hematologic malignancies (median age, 43 years) were enrolled between December 2011 and September 2013." | 2.82 | Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. ( Appelbaum, FR; Carpenter, PA; Flowers, ME; Furlong, T; Martin, PJ; McCune, JS; Mielcarek, M; O'Donnell, PV; Storb, R; Storer, BE, 2016) |
| "In AML patients, minimal residual disease (MRD; n = 10) at the time of HCT predicted higher relapse incidence (70% versus 18%) and lower OS (41% versus 79%) at 2 years, when compared with patients without MRD." | 2.79 | Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. ( Appelbaum, FR; Bar, M; Baumgart, J; Deeg, HJ; Delaney, C; Estey, EH; Fang, M; Gutman, J; Gyurkocza, B; Maziarz, RT; Milano, F; Nemecek, ER; Pagel, JM; Ramakrishnan, A; Sandmaier, BM; Scott, B; Storer, BE; Wood, B, 2014) |
| "Besides high rates of manageable infections due to late immune recovery, transplantation with CD34+ immunoselected grafts in HRNB children was feasible and did not affect long-term hematopoiesis." | 2.76 | CD34+ immunoselection of autologous grafts for the treatment of high-risk neuroblastoma. ( Berger, M; Demeocq, F; Halle, P; Kanold, J; Leverger, G; Marabelle, A; Merlin, E; Paillard, C; Piguet, C; Rousseau, R; Stephan, JL; Tchirkov, A, 2011) |
| " Here, we compared post-transplant outcomes after individualized versus fixed busulfan dosage in intermediate-risk AML who achieved CR prior to allograft focusing on pre-transplant flow-MRD." | 1.91 | Individualized busulfan dosing improves outcomes compared to fixed-dose administration in pre-transplant minimal residual disease-positive acute myeloid leukemia patients with intermediate-risk undergoing allogeneic stem cell transplantation in CR. ( Ayuk, F; Bacher, U; Badbaran, A; Dadkhah, A; Freiberger, P; Janson, D; Klyuchnikov, E; Kröger, N; Langebrake, C; Massoud, R; Wolschke, C, 2023) |
| " Plasma concentrations of BU at steady state (C(SS)BU) during the dosing interval were measured for each patient." | 1.30 | Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. ( Anasetti, C; Appelbaum, FR; Bensinger, WI; Bowden, R; Bryant, E; Buckner, CD; Chauncey, T; Clift, RA; Deeg, HJ; Doney, KC; Flowers, M; Gooley, T; Hansen, JA; Martin, PJ; McDonald, GB; Nash, R; Petersdorf, EW; Radich, J; Sanders, JE; Schoch, G; Slattery, JT; Soll, E; Stewart, P; Storb, R; Storer, B; Sullivan, KM; Thomas, ED; Witherspoon, RP, 1997) |
| "Clonal chromosome aberrations observed in patients who have relapsed after autologous bone marrow transplantation (ABMT) are usually related to the cytogenetic abnormalities observed at diagnosis." | 1.29 | Detection of occasional and clonal chromosome aberrations in patients with acute non-lymphocytic leukemia after autologous bone marrow transplantation. ( Gherlinzoni, F; Manfroi, S; Mangianti, S; Martinelli, G; Miggiano, MC; Pelliconi, S; Testoni, N; Tura, S; Visani, G; Zaccaria, A, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (36.36) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Meur, GL | 1 |
| Plesa, A | 1 |
| Larcher, MV | 1 |
| Fossard, G | 1 |
| Barraco, F | 1 |
| Loron, S | 1 |
| Balsat, M | 1 |
| Ducastelle-Leprêtre, S | 1 |
| Gilis, L | 1 |
| Thomas, X | 1 |
| Ghesquières, H | 1 |
| Tigaud, I | 1 |
| Hayette, S | 1 |
| Huet, S | 1 |
| Sujobert, P | 1 |
| Renault, M | 1 |
| Thérèse, RM | 1 |
| Michallet, M | 1 |
| Labussière-Wallet, H | 1 |
| Heiblig, M | 1 |
| Klyuchnikov, E | 1 |
| Langebrake, C | 1 |
| Badbaran, A | 1 |
| Dadkhah, A | 1 |
| Massoud, R | 1 |
| Freiberger, P | 1 |
| Ayuk, F | 1 |
| Janson, D | 1 |
| Wolschke, C | 1 |
| Bacher, U | 1 |
| Kröger, N | 1 |
| Gyurkocza, B | 1 |
| Gutman, J | 1 |
| Nemecek, ER | 1 |
| Bar, M | 1 |
| Milano, F | 1 |
| Ramakrishnan, A | 1 |
| Scott, B | 1 |
| Fang, M | 1 |
| Wood, B | 1 |
| Pagel, JM | 1 |
| Baumgart, J | 1 |
| Delaney, C | 1 |
| Maziarz, RT | 1 |
| Sandmaier, BM | 1 |
| Estey, EH | 1 |
| Appelbaum, FR | 3 |
| Storer, BE | 2 |
| Deeg, HJ | 2 |
| Mielcarek, M | 1 |
| Furlong, T | 1 |
| O'Donnell, PV | 1 |
| McCune, JS | 1 |
| Storb, R | 2 |
| Carpenter, PA | 1 |
| Flowers, ME | 1 |
| Martin, PJ | 2 |
| Deininger, MW | 1 |
| Marabelle, A | 1 |
| Merlin, E | 1 |
| Halle, P | 1 |
| Paillard, C | 1 |
| Berger, M | 1 |
| Tchirkov, A | 1 |
| Rousseau, R | 1 |
| Leverger, G | 1 |
| Piguet, C | 1 |
| Stephan, JL | 1 |
| Demeocq, F | 1 |
| Kanold, J | 1 |
| Fernández de Larrea, C | 1 |
| Tovar, N | 1 |
| Rozman, M | 1 |
| Rosiñol, L | 1 |
| Aróstegui, JI | 1 |
| Cibeira, MT | 1 |
| Rovira, M | 1 |
| Yagüe, J | 1 |
| Bladé, J | 1 |
| Greinix, HT | 1 |
| Keil, F | 1 |
| Brugger, SA | 1 |
| Reiter, E | 1 |
| Linkesch, W | 1 |
| Lechner, K | 1 |
| Schneider, B | 1 |
| Dieckmann, KU | 1 |
| Fischer, G | 1 |
| Schwarzinger, I | 1 |
| Haas, O | 1 |
| Hinterberger, W | 1 |
| Mannhalter, C | 1 |
| Geissler, K | 1 |
| Hocker, P | 1 |
| Jager, U | 1 |
| Kalhs, P | 1 |
| Testoni, N | 1 |
| Martinelli, G | 1 |
| Zaccaria, A | 1 |
| Miggiano, MC | 1 |
| Pelliconi, S | 1 |
| Visani, G | 1 |
| Manfroi, S | 1 |
| Gherlinzoni, F | 1 |
| Mangianti, S | 1 |
| Tura, S | 1 |
| Slattery, JT | 1 |
| Clift, RA | 1 |
| Buckner, CD | 1 |
| Radich, J | 1 |
| Storer, B | 1 |
| Bensinger, WI | 1 |
| Soll, E | 1 |
| Anasetti, C | 1 |
| Bowden, R | 1 |
| Bryant, E | 1 |
| Chauncey, T | 1 |
| Doney, KC | 1 |
| Flowers, M | 1 |
| Gooley, T | 1 |
| Hansen, JA | 1 |
| McDonald, GB | 1 |
| Nash, R | 1 |
| Petersdorf, EW | 1 |
| Sanders, JE | 1 |
| Schoch, G | 1 |
| Stewart, P | 1 |
| Sullivan, KM | 1 |
| Thomas, ED | 1 |
| Witherspoon, RP | 1 |
| Anguita, E | 1 |
| Villegas, A | 1 |
| Díaz-Mediavilla, J | 1 |
| González, FA | 1 |
| del Potro, E | 1 |
| Espinós, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation[NCT01427881] | Phase 2 | 43 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| Immunomonitoring of Children With Neuroblastoma for the Development of Antitumor Immunotherapy Strategies[NCT01295762] | 35 participants (Actual) | Interventional | 2011-05-31 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Chronic GVHD will be defined by National Institutes of Health (NIH) criteria and requiring systemic treatment. A reduction in the cumulative incidence of GVHD from ~35% to ~15% at 1 year would represent a reasonable goal. A sample size of 42 patients provides 90% power to observe such a difference with one-side 5% type-1 error. (NCT01427881)
Timeframe: At 1 year after transplantation
| Intervention | percent of patients (Number) |
|---|---|
| Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis) | 16 |
Disease-free survival will be evaluated as Kaplan-Meier estimates. (NCT01427881)
Timeframe: At 1 year post-transplant
| Intervention | percentage of patients (Number) |
|---|---|
| Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis) | 73.8 |
Donor engraftment is defined as the count (percent) of patients with full donor chimerism. Full donor chimerism is defined as at least 95% donor CD3 cells in peripheral blood. (NCT01427881)
Timeframe: At day 28
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis) | 6 |
Descriptive statistics will be used to assess the incidence of primary graft failure and secondary graft failure. Primary graft failure is defined as failure to achieve a sustained neutrophil count of >= 500/uL by >= 28 days post-transplant. Secondary graft failure is defined as the decline in neutrophil count to < 500/uL after achieving engraftment which is unrelated to infection or drug effect and is unresponsive to stimulation by growth factors. (NCT01427881)
Timeframe: By greater than or equal to 28 days post-transplant
| Intervention | percentage of patients (Number) |
|---|---|
| Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis) | 2 |
Defined as death in the absence of recurrent or progressive malignancy after HCT. Non-relapse morality will be assessed with the use of cumulative incidence plots. This secondary endpoint will be characterized and presented as a cumulative incidence. (NCT01427881)
Timeframe: At 2 years
| Intervention | percentage of patients (Number) |
|---|---|
| Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis) | 14 |
Overall survival will be evaluated as Kaplan-Meier estimates. (NCT01427881)
Timeframe: At 1 year post-transplant
| Intervention | percentage of patients (Number) |
|---|---|
| Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis) | 75.6 |
Recurrent or progressive malignancy will be assessed with the use of cumulative incidence plots. Recurrent malignancy will be defined by hematologic criteria. Recurrent malignancy will also be defined as any unplanned medical intervention designed to prevent progression of malignant disease in patients who have molecular, cytogenetic or flow-cytometric evidence of malignant cells after transplantation. (NCT01427881)
Timeframe: At 2 years
| Intervention | percentage of patients (Number) |
|---|---|
| Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis) | 17 |
Grades II-IV and III-IV GVHD will be assessed with the use of cumulative incidence plots. (NCT01427881)
Timeframe: Through day +100 post-transplant
| Intervention | percentage of patients (Number) | |
|---|---|---|
| Grades II-IV GVHD | Grades III-IV GVHD | |
| Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis) | 77 | 0 |
Descriptive statistics will be used to assess the median days of neutrophil and platelet recovery. The day of neutrophil recovery is defined as the first day of three consecutive lab values on different days, after the conditioning regimen-induced nadir of blood counts, that the absolute neutrophil count is > 500/uL. The day of platelet recovery is defined as the first day of three consecutive lab values on different days, after the conditioning regimen-induced nadir of blood counts, that the platelet count is >= 20,000/uL without platelet transfusion support in the seven days prior. (NCT01427881)
Timeframe: Up to day +100
| Intervention | days (Median) | |
|---|---|---|
| Neutrophil Engraftment | Platelet Engraftment | |
| Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis) | 19 | 14 |
1 review available for busulfan and Minimal Disease, Residual
| Article | Year |
|---|---|
Detection of bcr/abl mRNA in a case of chronic myelogenous leukemia in long-term remission: CML or sensitivity of detection?
Topics: Adult; Biomarkers, Tumor; Blotting, Southern; Busulfan; Female; Fusion Proteins, bcr-abl; Humans; Le | 1998 |
4 trials available for busulfan and Minimal Disease, Residual
| Article | Year |
|---|---|
Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic S | 2014 |
Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation.
Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Fr | 2016 |
CD34+ immunoselection of autologous grafts for the treatment of high-risk neuroblastoma.
Topics: Antigens, CD34; Busulfan; Child; Follow-Up Studies; Hematopoiesis; Hematopoietic Stem Cell Transplan | 2011 |
Multiple myeloma in serologic complete remission after autologous stem cell transplantation: impact of bone marrow plasma cell assessment by conventional morphology on disease progression.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Examination; B | 2011 |
6 other studies available for busulfan and Minimal Disease, Residual
| Article | Year |
|---|---|
Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric Study.
Topics: Amsacrine; Busulfan; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, | 2023 |
Individualized busulfan dosing improves outcomes compared to fixed-dose administration in pre-transplant minimal residual disease-positive acute myeloid leukemia patients with intermediate-risk undergoing allogeneic stem cell transplantation in CR.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, | 2023 |
Chronic myeloid leukemia: an historical perspective.
Topics: Antineoplastic Agents; Busulfan; History, 19th Century; History, 20th Century; Humans; Leukemia, Mye | 2008 |
Long-term leukemia-free survival after allogeneic marrow transplantation in patients with acute myelogenous leukemia.
Topics: Acute Disease; Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclosporine; Disease | 1996 |
Detection of occasional and clonal chromosome aberrations in patients with acute non-lymphocytic leukemia after autologous bone marrow transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Bu | 1996 |
Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Cause of Death; Cyclophosphamide; Female; Graft Reject | 1997 |